The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer

被引:3
作者
Amanam, Idoroenyi [1 ]
Gupta, Rohan [1 ]
Mambetsariev, Isa [1 ]
Salgia, Ravi [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Res Therapeut, 1500 E Duarte Rd, Duarte, CA 91010 USA
关键词
alectinib; ALK; ALTA; brigatinib; central nervous system metastases; ceritinib; crizotinib; EML4-ALK rearrangement; lung cancer; NSCLC; EML4-ALK FUSION GENE; RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA; CRIZOTINIB RESISTANCE; CSF CONCENTRATION; OPEN-LABEL; INHIBITOR; CHEMOTHERAPY; MUTATIONS; IDENTIFICATION;
D O I
10.2217/fon-2017-0545
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer remains the leading cause of cancer deaths in the world with 1.69 million deaths in 2015. A total of 85% of lung cancer cases are non-small-cell lung cancers (NSCLCs). Driver mutations associated with anaplastic lymphoma kinase (ALK) have been identified in a variety of malignancies, including NSCLC. An ALK inhibitor (crizotinib, ceritinib and alectinib) is the preferred therapeutic approach to those advanced ALK fusion variant-positive NSCLC patients. Brigatinib, a next-generation ALK inhibitor, shows promising activity in ALK-rearranged NSCLC that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients.
引用
收藏
页码:1897 / 1908
页数:12
相关论文
共 55 条
  • [1] [Anonymous], 2017, CANCER
  • [2] [Anonymous], 2017, BROWSE SEER CANC STA
  • [3] Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429
  • [4] Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
    Bendell, Johanna C.
    Kim, Tae Won
    Goh, Boon C.
    Wallin, Jeffrey
    Oh, Do-Youn
    Han, Sae-Won
    Lee, Carrie B.
    Hellmann, Matthew David
    Desai, Jayesh
    Lewin, Jeremy Howard
    Solomon, Benjamin J.
    Chow, Laura Quan Man
    Miller, Wilson H.
    Gainor, Justin F.
    Flaherty, Keith
    Infante, Jeffrey R.
    Das-Thakur, Meghna
    Foster, Paul
    Cha, Edward
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
    Choi, Young Lim
    Soda, Manabu
    Yamashita, Yoshihiro
    Ueno, Toshihide
    Takashima, Junpei
    Nakajima, Takahiro
    Yatabe, Yasushi
    Takeuchi, Kengo
    Hamada, Toru
    Haruta, Hidenori
    Ishikawa, Yuichi
    Kimura, Hideki
    Mitsudomi, Tetsuya
    Tanio, Yoshiro
    Mano, Hiroyuki
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1734 - 1739
  • [6] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets
    Cohen, MH
    Williams, GA
    Sridhara, R
    Chen, G
    Pazdur, R
    [J]. ONCOLOGIST, 2003, 8 (04) : 303 - 306
  • [7] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
    Costa, Daniel B.
    Shaw, Alice T.
    Ou, Sai-Hong I.
    Solomon, Benjamin J.
    Riely, Gregory J.
    Ahn, Myung-Ju
    Zhou, Caicun
    Shreeve, S. Martin
    Selaru, Paulina
    Polli, Anna
    Schnell, Patrick
    Wilner, Keith D.
    Wiltshire, Robin
    Camidge, D. Ross
    Crino, Lucio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1881 - 1888
  • [8] CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
    Costa, Daniel B.
    Kobayashi, Susumu
    Pandya, Shuchi S.
    Yeo, Wee-Lee
    Shen, Zhongzhou
    Tan, Weiwei
    Wilner, Keith D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : E443 - E445
  • [9] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Pilling, Amanda B.
    Aisner, Dara L.
    Kutateladze, Tatiana G.
    Le, Anh T.
    Weickhardt, Andrew J.
    Kondo, Kimi L.
    Linderman, Derek J.
    Heasley, Lynn E.
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1472 - 1482